Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 28 June 2018, 06:00 HKT/SGT
Share:
    

Source: Novotech
Novotech at DIA18 announces Asia Partnerships on Target to Reach 1.4 Bil Patients

BOSTON, June 28, 2018 - (ACN Newswire) - Asia-Pacific CRO Novotech announced at DIA18 (24-28 June, Boston Convention and Exhibition Center) that it has signed Memorandums of Understanding (MOUs) with five of the leading medical institutions in the region. The MOU partnership program is designed to give Novotech clients access to an additional 1.4 billion patients, and specialist investigators with advanced clinical research sites.

Novotech made the announcement at the DIA conference (Booth 1904). https://novotech-cro.com/welcome

Novotech Director of Business Development Barry Murphy who is attending the conference said: "Novotech has now signed five MOUs with medical institutions across the region with two more being signed in Thailand and the Philippines next month.

"Asia is the highest growth region for clinical research in the world, and as the Asia-Pacific CRO, we bring access to the key sites and KOLs to our clients via well-developed partnerships and relationships on the ground in Asia. Our MOUs further formalise these relationships.

"Some of the new MOUs are with the largest institutes in the region, such as the China Medical University Hospital in Taiwan which has more than a 2,000-bed facilities with dedicated clinical trials centres."

The partnerships are designed to give Novotech clients:
- Faster start-up times
- Access to significant patient database
- World-class clinical research - regulatory compliance with FDA, PMDA and EMEA
- Outstanding recruiters across many therapeutic areas: breast cancer, lung cancer, colorectal cancer, Hepatitis, SLE, RA, Stroke, Diabetes, etc.
- Leading principal investigators

The partnerships involve the provision of professional and medical clinical trial advice to the Novotech team including feasibility, principal investigator selection, and assistance with patient recruitment, while Novotech will promote the clinical research capabilities of these institutions internationally.

Novotech Executive Director, Asia Operations Dr. Yooni Kim said: "The partnerships mean Novotech has dedicated clinical experts within these leading hospital organisations to support and prioritise rapid clinical processes for Novotech biopharma clients.

"Novotech is the Asia-Pacific CRO, so is committed to establishing ongoing engagement with leading medical institutions in each country across the Asia-Pacific region. We have offices and teams on the ground as well as MOUs and long-term relationships with major hospitals that directly benefit our clients.

"Our in-country relationships enable a more comprehensive understanding of local regulatory changes, access to leading PIs, strong site connections, and productive patient populations to deliver success for our clients within timelines and budgets," Dr. Kim said.

Novotech is the Asia-Pacific specialist contract research organization (CRO) established in 1996, headquartered in Australia with offices in 11 countries across the region.

See the latest data on Asia clinical trials here: http://www.novotech-cro.com/resources.

About Novotech - www.novotech-cro.com
Headquartered in Sydney, Novotech is internationally recognised as the leading regional full-service contract research organisation (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia Pacific region.

Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech's strong Asia Pacific presence includes running clinical trials in all key regional markets. Novotech also has worldwide reach through the company's network of strategic partners.

For RFP enquiries: see https://novotech-cro.com/welcome

Novotech DIA Contact
Director of Business Development
Barry Murphy
[email protected]
USA: +1-415-527-8320

Media Contact
Susan Fitzpatrick-Napier
[email protected]
AU: +61 2 8218 2144
USA: +1 415 951 3228
ASIA: +65 3159 3427


June 28, 2018 06:00 HKT/SGT
Topic: Press release summary
Sectors: HealthCare
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Novotech
July 11, 2019 11:00 HKT/SGT
Novotech CRO partners Skin Research Institute of Singapore (SRIS) for Skin Disorder Research
May 31, 2019 07:00 HKT/SGT
Novotech Awarded Asia-Pacific Biotech CRO of the Year - Announced at ASCO
Apr 18, 2019 04:00 HKT/SGT
Novotech CRO strengthens South Korean Clinical Capabilities, partners with 2 Major Hospitals
Mar 25, 2019 18:00 HKT/SGT
Novotech CNS USA Appoints Dr Robert Malone to its Washington, DC BioDesk
Dec 17, 2018 08:00 HKT/SGT
Novotech CRO Launches Largest Oracle Trial Management and Monitoring Cloud Service Implementation in Asia-Pacific
Nov 28, 2018 11:02 HKT/SGT
Novotech CRO Announces 41 Clinical Staff and 81 Projects in South Korea
Oct 19, 2018 07:00 HKT/SGT
Novotech and CNS deal expands CRO services for Biopharma Clients across Asia-Pacific
Aug 23, 2018 13:00 HKT/SGT
Novotech the Asia-Pacific CRO named Top 10 CRO
Aug 9, 2018 13:00 HKT/SGT
Sponsors Recommend Novotech for CRO Leadership Award
July 19, 2018 06:00 HKT/SGT
Novotech Partners with Asian Eye Institute for Accelerated Ophthalmic Drug and Devices Clinical Trials
More news >>
 News Alerts
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: